Cell-penetrating peptides (CPPs) are short, mostly positively charged peptides that can slip through cell membranes and drag attached drugs inside. The quick answer: CPPs have been studied since 1988 and have reached phase 3 trials, but none has been FDA-approved.[2][5] The most advanced, the stroke drug nerinetide, did not improve recovery overall in two phase 3 trials with 1,105 and 850 patients.[7][8]
This page is part of our peptide basics hub. For other ways peptides deliver drugs, see peptide-drug conjugates.
Bottom line
- Established: CPPs can carry cargo into cells in lab and animal studies.[1]
- Not yet proven in people: no CPP-based drug has shown clear benefit in a phase 3 trial or won FDA approval.[5][8]
- Mixed: nerinetide’s first trial hinted at benefit in a subgroup; the confirmatory trial was neutral.[7][8]
- Emerging: CPPs are being used to deliver antisense “programmable antibiotics” in lab research.[10]
How cell-penetrating peptides were discovered
Most drugs that act inside cells must be small and fat-soluble. Large molecules, such as proteins and gene-silencing molecules, usually can’t cross the cell’s outer membrane.
In 1988, two research teams found that the HIV Tat protein could enter cultured cells on its own and reach the nucleus.[2][3] Scientists later traced this ability to a short, arginine-rich stretch now called the TAT peptide. In 1994, a 16-amino-acid piece of the fruit-fly Antennapedia protein, later named penetratin, was shown to cross membranes as well.[4] These discoveries launched a field of more than 30 years of research.[5]
How they get in
CPPs usually carry many positive charges that stick to the negatively charged cell surface. From there, they enter by two broad routes:[1]
- Direct translocation: passing straight through the membrane, mainly at higher concentrations.
- Endocytosis: being swallowed into a small bubble (endosome). Much of the cargo can stay trapped there and be broken down, a major reason why CPP drugs often work less well in the body than in a dish.
| CPP | Origin | Notes |
|---|---|---|
| TAT | HIV-1 Tat protein | The first CPP; used in nerinetide[2][6] |
| Penetratin | Fruit-fly Antennapedia protein | 16 amino acids[4] |
| Polyarginine | Synthetic | Chains of arginine; simple to make[1] |
| (KFF)3K, (RXR)4 | Synthetic | Used to carry antisense molecules into bacteria[10] |
Key clinical trials: nerinetide for stroke
Nerinetide (NA-1, also called Tat-NR2B9c) joins a short peptide that disrupts a nerve-damage signaling complex to the TAT sequence so it can enter brain cells.[6]
ESCAPE-NA1 (2020). In 1,105 people with stroke undergoing clot removal (thrombectomy), 61.4% on nerinetide vs 59.2% on placebo reached good functional recovery at 90 days, which was not a significant difference. The researchers saw signs that the clot-dissolving drug alteplase blocked nerinetide’s effect, suggesting a possible benefit in people who did not receive alteplase.[7]
ESCAPE-NEXT (2025). To test that idea, 850 thrombectomy patients who had not received a clot-dissolving drug were randomized. Good recovery occurred in 45% with nerinetide vs 46% with placebo, again no benefit.[8]
FRONTIER (2025). Paramedics gave nerinetide or placebo in the ambulance within three hours of suspected stroke in 532 people. Favorable outcomes were similar: 57% vs 58%.[9]
Other uses being studied
- Cancer: CPPs have been linked to tumor-killing peptides and chemotherapy. For example, the experimental peptide PNC-27 uses penetratin as its entry sequence; it has no completed human efficacy trials.
- Antibiotics: antisense molecules called PNAs can silence essential bacterial genes, but need a CPP to get inside. A 2026 lab study found that bacteria evolved reduced uptake against one CPP, (KFF)3K, while another, (RXR)4, held up better, showing that the choice of carrier peptide affects resistance.[10] Our guide to antimicrobial peptides research covers resistance more broadly.
- Eye, ear and skin: reviews describe early trials of CPP-based drugs for these sites, chosen because local delivery avoids some of the problems of injecting into the bloodstream.[5]
Why results in dishes don’t carry over
A CPP that delivers cargo efficiently into cultured cells faces three extra problems in a person. First, dose: lab experiments often use concentrations far higher than can be reached safely in blood. Second, distribution: once injected, a CPP meets blood proteins, enzymes and kidneys before it reaches the target organ, and only a fraction arrives. Third, timing: in conditions such as stroke, the drug has to reach injured tissue within a narrow window, which is part of why nerinetide was tested in ambulances.[1][9]
These gaps are a general lesson for peptide research, not just CPPs. Promising cell and animal results are a starting point, not evidence that a treatment works.
Limitations and safety
- Poor selectivity: CPPs enter most cell types, not just diseased ones, so drugs can reach unintended tissues.[1]
- Endosomal trapping: much of the cargo may never reach its target inside the cell.[1]
- Stability: like other peptides, CPPs are broken down by enzymes in blood.
- Safety in trials: serious adverse events occurred about equally in the nerinetide and placebo groups in both phase 3 stroke trials.[7][8]
What’s next
The nerinetide program showed how hard it is to translate a CPP that works in animals into a benefit for patients. Current research focuses on making CPPs more selective, for example by adding sequences that are only activated by tumor enzymes, and on escaping endosomes so more cargo reaches its target.[1][5] CPP carriers for antisense antibiotics are an active lab area, where the carrier choice itself affects how quickly bacteria adapt.[10]
For related delivery approaches, see our guides to cyclic peptides, which resist breakdown, and peptide vaccines. Our natural vs synthetic peptides guide explains the chemistry behind these modifications.
Questions to discuss with a clinician
- Is there a trial of a cell-penetrating peptide drug relevant to my condition?
- What is known about where such a drug goes in the body?
- Why isn’t a “cell-penetrating” peptide sold online a treatment?
- For stroke, what treatments do have proven benefit?
